Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (4953)	11/30/1997 7:43:00 AM
From: Robert K.	Read Replies (1) \| Respond to of 17367

In Europe I believe its called meningococcal sepsis. Thats right sepsis. Excellent responses Cacaito. Heres some selected responses. -theory is sickest patients (who would have died) lived -I agree the sooner to start the better, I agree, the fact that they need "additional"parental consent slows administration time -I believe some bpi products do have activity against chalmydie(sp) -The weird thing about bpi21 is that it has IMO very strong research results, and 'should' work even better in vivo (lbp etc) but in vivo results dont seem to be as good as one might expect. To me there seems to be a missing piece to the puzzle, which is solve-able. -Great reminder one death was on fringe of trial parameter at best. -I agree xoma has not and is not making adventerous claims IMO -Tharos-I agree, that MD does not seem to be involved in bpi trial, refers to "a single agent" but forgets or overlooks the fact that bpi has "multiple actions". However one must respect the source (the persons credentials and the peer reviewed source). I tend to agree with you but am respecting the source.